Nested Therapeutics utilizes a proprietary drug discovery platform that employs genomics, computational biophysics, and machine learning to identify novel driver mutations and druggable pockets in cancer pathways. This approach addresses the challenge of developing targeted therapies for the vast majority of recurrent cancer-associated mutations that currently lack FDA-approved treatments.
Funding
$128.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Despite advances in precision medicine, the majority of recurrent cancer-associated mutations lack FDA-approved targeted therapies, leaving a significant portion of advanced cancer patients without effective treatment options. Identifying novel driver alterations and druggable pockets remains a bottleneck in expanding the reach of precision oncology.
Solution
Nested Therapeutics is developing targeted therapeutics for cancer by employing a drug discovery platform that integrates genomics, computational biophysics, machine learning, and chemical biology. The platform maps mutational clusters onto the structural proteome to identify druggable pockets and cancer-driving mechanisms, and then designs novel drugs optimized for those pockets. Nested's lead program, NST-628, is a non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue targeting multiple components in the RAS/MAPK pathway and is currently in Phase 1 clinical trials. The company is also developing a mutation-selective program in the p53 pathway, targeting a transcriptional regulator frequently mutated in cancer.
Target Audience
Nested Therapeutics focuses on developing therapies for cancer patients with recurrent mutations that currently lack effective treatment options.
Features
- Drug discovery platform integrating genomics, computational biophysics, machine learning, and chemical biology
- Identification of novel druggable pockets and cancer-driving mechanisms through mapping mutational clusters onto the structural proteome
- Design of novel drugs optimized for identified druggable pockets
- Lead program NST-628: a non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue
- NST-628 targets multiple critical components in the RAS/MAPK pathway
- NST-628 is currently being evaluated in a global two-part Phase 1 study in patients with MAPK-driven solid tumors
- Mutation-selective program in the p53 pathway, targeting a transcriptional regulator frequently mutated in cancer